Ptc Therapeutics (PTCT) Receivables - Net (2013 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Receivables - Net of $239.0 million for Q2 2026, up 21.88% year-over-year from $196.1 million in Q2 2025, and up 8.7% quarter-over-quarter from $219.9 million in Q1 2026.
Ptc Therapeutics (PTCT) Receivables - Net (2013 - 2026) Analysis & Trends
Ptc Therapeutics' Receivables - Net history runs 14 years deep, the most recent figure standing at $239.0 million for Q2 2026.
- In Q2 2026, Receivables - Net rose 21.88% year-over-year to $239.0 million; the TTM figure through Jun 2026 stood at $239.0 million (up 21.88% YoY), while the FY2025 annual figure was $181.6 million, up 14.55% from the prior year.
- Receivables - Net for Q2 2026 stood at $239.0 million, up from $219.9 million in the prior quarter.
- The five-year high for Receivables - Net was $239.0 million in Q2 2026, with the low at $124.5 million in Q3 2022.
- The 5-year median for Receivables - Net is $184.4 million (2024), against an average of $180.9 million.
- The sharpest annual moves came in 2022 and 2024: Receivables - Net soared 72.51% in 2022, then dropped 2.08% in 2024.
- Ptc Therapeutics' Receivables - Net stood at $155.6 million in 2022, then gained by 3.35% to $160.8 million in 2023, then slipped by 1.41% to $158.6 million in 2024, then rose by 14.55% to $181.6 million in 2025, then jumped by 31.62% to $239.0 million in 2026.
- Business Quant data shows PTCT's Receivables - Net at $239.0 million in Q2 2026, $219.9 million in Q1 2026, and $181.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 239.04 Mn |
| Jun 30, 2026 | 239.04 Mn |
| Mar 31, 2026 | 219.92 Mn |
| Mar 31, 2026 | 219.92 Mn |
| Dec 31, 2025 | 181.62 Mn |
| Dec 31, 2025 | 181.62 Mn |
| Sep 30, 2025 | 203.07 Mn |
| Sep 30, 2025 | 203.07 Mn |
| Jun 30, 2025 | 196.13 Mn |
| Jun 30, 2025 | 196.13 Mn |
| Mar 31, 2025 | 210.50 Mn |
| Mar 31, 2025 | 210.50 Mn |
| Dec 31, 2024 | 158.55 Mn |
| Dec 31, 2024 | 158.55 Mn |
| Sep 30, 2024 | 199.98 Mn |
| Sep 30, 2024 | 199.98 Mn |
| Jun 30, 2024 | 187.15 Mn |
| Jun 30, 2024 | 187.15 Mn |
| Mar 31, 2024 | 197.66 Mn |
| Mar 31, 2024 | 197.66 Mn |